
Velnof 50mg Tablet ER
Marketer
Leeford Healthcare Ltd
Salt Composition
Desvenlafaxine (50mg)
Overview Velnof 50mg Tablet ER
Deprexis 50mg Extended-Release Tablets are a prescription medication indicated for the management of depressive disorders. This medication works by elevating levels of serotonin and norepinephrine, neurotransmitters that promote a sense of calm and neurological relaxation, thereby alleviating depressive symptoms. Deprexis 50mg Extended-Release Tablets are administered orally, with or without food, at the same time each day to ensure consistent blood levels. If a dose is missed, take it as soon as possible; however, avoid doubling up on doses. Complete the prescribed course of treatment, even if symptoms improve. Abrupt discontinuation should be avoided; consult your physician before stopping this medication to prevent symptom exacerbation. Common adverse effects include nausea, vomiting, sleep disturbances, and constipation. Increased blood pressure, particularly during the initial month, is possible; regular monitoring is recommended. Drowsiness and dizziness may occur; refrain from operating machinery or engaging in activities requiring alertness until the medication's effects are known. Report any significant mood changes to your doctor immediately, as they may indicate suicidal ideation.
Primary Ingredients of Velnof 50mg Tablet ER
No text provided to rephrase.
Uses of Velnof 50mg Tablet ER
Clinical depression
Major Benefits of Velnof 50mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 50mg extended-release Velnof tablet whole; avoid chewing, crushing, or breaking it. While food is not a requirement, consistency is key—take it at the same time each day.
Common Side effects of Velnof 50mg Tablet ER:
- Anxiety
- Constipation
- Decreased appetite
- Dizziness
- Increased sweating
- Insomnia (difficulty in sleeping)
- Nausea
- Sexual dysfunction
- Vomiting
How to use Velnof 50mg Tablet ER:
Consume this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Velnof 50mg Extended-Release Tablets can be administered with or without food, though consistent timing is recommended.
How Velnof 50mg Tablet ER works:
Extended-release Velnof 50mg tablets function by elevating brain concentrations of serotonin and noradrenaline, neurotransmitters crucial for preserving cognitive equilibrium.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when combining Velnof 50mg Extended-Release Tablets with alcohol. Seek medical advice.
PregnancyCONSULT YOUR DOCTOR
Extended-release Velnof 50mg tablets may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Velnof 50mg tablets are likely unsafe for breastfeeding mothers. Preliminary human evidence indicates potential transfer to breast milk, posing a risk to the infant.
DrivingUNSAFE
Extended-release Velnof 50mg tablets can reduce attentiveness, impair vision, and induce drowsiness or dizziness. Refrain from driving if these effects are experienced.
KidneyCAUTION
Extended-release Velnof 50mg tablets require careful administration for individuals with impaired renal function. Dosage modification of Velnof 50mg ER tablets may be necessary. Physician consultation is recommended.
LiverCAUTION
Patients with hepatic impairment should use Velnof 50mg Extended-Release tablets cautiously; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Velnof 50mg Tablet ER :
Should you forget a Velnof 50mg Extended-Release Tablet, take it immediately upon remembering. If, however, your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.
Facts to Know About Velnof 50mg Tablet ER
| Label | Value |
|---|---|
| Chemical Type | Cyclohexanol Derivatives |
| Developing Habits | No. |
| Treatment Category | Neuroscience of the Central Nervous System |
